Senolytics extend healthspan beyond cancer—but tissue context determines whether they help or harm

Senescent cells drive aging, and killing them extends life. But new evidence reveals a paradox: senolytics boost cardiac regeneration yet impair skin wound healing. The difference isn't the drug—it's whether senescence is chronic (pathological) or transient (physiological). This reframes the therapeutic question from "how much clearance?" to "when and where?"